Group 1 - Company Gilead Sciences-B (01672.HK) announced positive topline pharmacokinetic (PK) data from a randomized, double-blind, placebo-controlled Phase Ib multiple ascending dose (MAD) study of ASC30 in obese subjects (BMI: 30-40 kg/m2) [1] - In the Phase Ib MAD study, the drug exposure levels (AUC0-24h) at steady state were 3,560 ng.h/mL for cohort 1 (20 mg) and 5,060 ng.h/mL for cohort 2 (40 mg) [1] - After 28 days of treatment, the average weight loss was 4.5% for cohort 1 and 6.5% for cohort 2, indicating that higher drug exposure leads to more significant weight loss effects [1] Group 2 - The founder and CEO of Gilead, Dr. Wu Jinzi, stated that higher drug exposure levels for small molecule GLP-1 receptor agonists, including orforglipron, result in more significant weight loss effects [2] - In head-to-head studies in non-human primates, ASC30 showed higher drug exposure than orforglipron, which translated into human clinical studies [2] - Cross-trial comparisons indicated that ASC30's drug exposure in humans is approximately 2.3 to 3.3 times that of orforglipron, suggesting competitive and differentiated potential for ASC30 in treating obesity [2]
歌礼制药-B(01672.HK):ASC30每日一次口服片在美国Ib期多剂量递增研究中展现出良好且具差异化的药代动力学特征